IFNA1 and adult T-cell leukemia/lymphoma: However, new agents are developed for ATLL treatments and relapse prevention such as purine analogs, histone deacetylase inhibitors, arsenic/IFN combination, monoclonal antibodies including anti-CC chemokine receptor 4 (CCR4 mAb/Mogamulizumab/Moga) and toxin fusion proteins [6, 9, 10].